Extendicare (TSE:EXE – Get Free Report) had its price target increased by equities research analysts at BMO Capital Markets from C$15.00 to C$21.00 in a research note issued to investors on Monday,BayStreet.CA reports. BMO Capital Markets’ price target would indicate a potential upside of 5.90% from the company’s current price.
Several other equities analysts also recently issued reports on EXE. CIBC upped their price objective on shares of Extendicare from C$18.00 to C$22.00 in a research note on Thursday. National Bankshares increased their price target on Extendicare from C$16.10 to C$17.50 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. TD Securities lifted their price objective on Extendicare from C$15.00 to C$19.00 in a research report on Thursday. Finally, Cibc World Mkts upgraded Extendicare to a “strong-buy” rating in a research report on Monday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of C$18.10.
Read Our Latest Stock Analysis on EXE
Extendicare Price Performance
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Read More
- Five stocks we like better than Extendicare
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Energy Giants Amp Up Dividends—Here’s What It Means for Investors
- How to buy stock: A step-by-step guide for beginners
- Why These 3 Tech Stocks Could Be the Best Opportunities You’re Overlooking
- Financial Services Stocks Investing
- Does Insider Buying Signal Value in the WD-40 Company?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
